Skip to main content

Development of very promising humanized therapeutic mAbs efficiently neutralizing a novel immunosuppressive pathway involved in a wide range of cancers

Objective

Studies have demonstrated the importance of CD73 in the spread of cancer. Overexpressed in numerous cancer types, this enzyme leads to the production of high amounts of extracellular Adenosine, creating an immunosuppressive microenvironment, and contributing to tumor proliferation and dissemination. Neutralizing its activity represents a highly potent and innovative therapy.
Following on the recent success of mAbs targeting immune checkpoint (PD1, CTLA4), TumAdoR aims to discover, characterize and produce humanized anti-hCD73 mAbs that will be assessed for their efficacy and safety in relevant mouse preclinical tumor models. It will result in the development of anti-CD73 drug candidates that will strengthen the immune system, stop cancer cell progression and prevent relapse through restoration of immune memory. TumAdoR aims at paving the way to first-in-human clinical trials of potent mAb candidates, and validating a new cancer immunotherapy, suitable for a wide range of cancers.

More precisely, TumAdoR will:
•Reinforce knowledge about CD73 role as an immune checkpoint target
•Correlate CD73 expression with clinical outcome and validate the tumor patients most likely to benefit from CD73 blockade
•Discover and develop mAbs neutralizing hCD73
•Develop relevant preclinical tumor models to validate the in vivo efficacy and safety of anti-CD73 mAbs candidate(s)
•Develop and standardize tools to assess CD73 expression, and monitor immune parameters in patients

TumAdoR addresses topic 1 by developing antibodies neutralizing CD73, and topic 3 by fighting against immune evasion in tumor host microenvironment. The high-level consortium including 3 SMEs possesses all the scientific and clinical expertises, industrial competences, biological and enzymatic assays, biological and clinical resources, and preclinical models to discover and produce mAbs, and investigate the functions of CD73, and the therapeutic impact of its neutralization.

Field of science

  • /medical and health sciences/basic medicine/immunology
  • /medical and health sciences/clinical medicine/oncology/cancer

Call for proposal

FP7-HEALTH-2013-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

CENTRE DE LUTTE CONTRE LE CANCER LEON BERARD
Address
Rue Laennec 28
69373 Lyon
France
Activity type
Research Organisations
EU contribution
€ 1 863 991,62
Administrative Contact
Marina Rousseau (Dr.)

Participants (7)

INNATE PHARMA
France
EU contribution
€ 1 566 684,40
Address
Avenue De Luminy 117
13009 Marseille
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Nicolas Dams (Mr.)
TURUN YLIOPISTO
Finland
EU contribution
€ 781 674,80
Address
Yliopistonmaki
20014 Turku
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mari Riipinen (Dr.)
GENEWAKE GMBH

Participation ended

Germany
EU contribution
€ 173 432,96
Address
Floriansbogen 2-4
82061 Neuried
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Robert Loewe (Dr.)
UNIVERSITE DE LAUSANNE
Switzerland
EU contribution
€ 719 116,22
Address
Quartier Unil-centre Bâtiment Unicentre
1015 Lausanne
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Pedro Romero (Prof.)
THE UNIVERSITY OF TEXAS SYSTEM
United States
EU contribution
€ 515 590
Address
Colorado Street 601
78701 2982 Austin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tyler Curiel (Dr.)
POLYGENE AG
Switzerland
EU contribution
€ 114 400
Address
Riedmattstrasse 9
8153 Rümlang
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Stefan Selbert (Dr.)
AYMING
France
EU contribution
€ 244 000
Address
185 Avenue Des Gresillons
92622 Gennevilliers Cedex
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Fabienne Brutin (Ms.)